These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 17319458)

  • 21. Endothelial dysfunction and the metabolic syndrome.
    McVeigh GE; Cohn JN
    Curr Diab Rep; 2003 Feb; 3(1):87-92. PubMed ID: 12643151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes.
    Rosenson RS; Reasner CA
    Curr Opin Cardiol; 2004 Sep; 19(5):480-7. PubMed ID: 15316457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory markers and cardiovascular risk in the metabolic syndrome.
    Espinola-Klein C; Gori T; Blankenberg S; Munzel T
    Front Biosci (Landmark Ed); 2011 Jan; 16(5):1663-74. PubMed ID: 21196255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of cardiovascular risk factors in patients with metabolic syndrome.
    de la Sierra A; Ruilope LM
    Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):209-14. PubMed ID: 17630947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cardiovascular continuum in Asia--a new paradigm for the metabolic syndrome.
    Cheung BM
    J Cardiovasc Pharmacol; 2005 Aug; 46(2):125-9. PubMed ID: 16044022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing atherosclerosis in patients with type 2 diabetes mellitus and metabolic syndrome.
    Venkatapuram S; Shannon RP
    Am J Ther; 2006; 13(1):64-71. PubMed ID: 16428924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
    Grundy SM
    Clin Cornerstone; 2006; 8 Suppl 1():S21-7. PubMed ID: 16903166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic syndrome: a marker of patients at high cardiovascular risk.
    Lau DC; Yan H; Dhillon B
    Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):85B-90B. PubMed ID: 16498518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 24-month metabolic benefits of the healthy living partnerships to prevent diabetes: A community-based translational study.
    Pedley CF; Case LD; Blackwell CS; Katula JA; Vitolins MZ
    Diabetes Metab Syndr; 2018 May; 12(3):215-220. PubMed ID: 28964720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic syndrome and progression of atherosclerosis among middle-aged US adults.
    Fan AZ
    J Atheroscler Thromb; 2006 Feb; 13(1):46-54. PubMed ID: 16505591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does a diagnosis of metabolic syndrome have value in clinical practice?
    Grundy SM
    Am J Clin Nutr; 2006 Jun; 83(6):1248-51. PubMed ID: 16762931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic syndrome, diabetes and cardiovascular events: current controversies and recommendations.
    Zarich SW
    Minerva Cardioangiol; 2006 Apr; 54(2):195-214. PubMed ID: 16778752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular risk associated with the metabolic syndrome.
    Lindsay RS; Howard BV
    Curr Diab Rep; 2004 Feb; 4(1):63-8. PubMed ID: 14764282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes.
    Mikhailidis DP; Press M
    Expert Opin Pharmacother; 2007 Dec; 8(17):3009-20. PubMed ID: 18001259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing cardiovascular risk in patients with metabolic syndrome.
    Bassand JP
    Clin Cornerstone; 2006; 8 Suppl 1():S7-14. PubMed ID: 16903164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Roles of angiopoietin-like protein 2 (Angptl2) in chronic inflammation and atherosclerotic diseases].
    Oike Y
    Nihon Rinsho; 2011 Jan; 69(1):163-7. PubMed ID: 21226278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues.
    Aguilar-Salinas CA; Mehta R; Rojas R; Gómez-Pérez FJ; Olaiz G; Rull JA
    Curr Diabetes Rev; 2005 May; 1(2):145-58. PubMed ID: 18220590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathophysiology of the metabolic syndrome.
    McCracken E; Monaghan M; Sreenivasan S
    Clin Dermatol; 2018; 36(1):14-20. PubMed ID: 29241747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic syndrome in the acute care setting.
    Selig PM
    AACN Clin Issues; 2006; 17(1):79-85. PubMed ID: 16462412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin resistance and chronic cardiovascular inflammatory syndrome.
    Fernández-Real JM; Ricart W
    Endocr Rev; 2003 Jun; 24(3):278-301. PubMed ID: 12788800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.